Tbio IKZF1 DNA-binding protein Ikaros

Protein Summary

Description

Transcription regulator of hematopoietic cell differentiation (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265, PubMed:19141594). Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2 chromatin-remodeling complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex), to the beta-globin locus in adult erythrocytes. Increases normal apoptosis in adult erythroid cells. Confers early temporal competence to retinal progenitor cells (RPCs) (By similarity). Function is isoform-specific and is modulated by dominant-negative inactive isoforms (PubMed:17135265, PubMed:17934067). This gene encodes a transcription factor that belongs to the family of zinc-finger DNA-binding proteins associated with chromatin remodeling. The expression of this protein is restricted to the fetal and adult hemo-lymphopoietic system, and it functions as a regulator of lymphocyte differentiation. Several alternatively spliced transcript variants encoding different isoforms have been described for this gene. Most isoforms share a common C-terminal domain, which contains two zinc finger motifs that are required for hetero- or homo-dimerization, and for interactions with other proteins. The isoforms, however, differ in the number of N-terminal zinc finger motifs that bind DNA and in nuclear localization signal presence, resulting in members with and without DNA-binding properties. Only a few isoforms contain the requisite three or more N-terminal zinc motifs that confer high affinity binding to a specific core DNA sequence element in the promoters of target genes. The non-DNA-binding isoforms are largely found in the cytoplasm, and are thought to function as dominant-negative factors. Overexpression of some dominant-negative isoforms have been associated with B-cell malignancies, such as acute lymphoblastic leukemia (ALL). [provided by RefSeq, May 2014]

Uniprot Accession IDs

• Q13422
• A4D260
• B4E0Z1
• D3DVM5
• O00598
• Q53XL2
• Q69BM4
• Q8WVA3

Gene Name

• IKZF1

Ensembl ID

• ENST00000331340
• ENSP00000331614
• ENSG00000185811
• ENST00000343574
• ENSP00000342750
• ENST00000349824
• ENSP00000342485
• ENST00000357364
• ENSP00000349928
• ENST00000359197
• ENSP00000352123
• ENST00000438033
• ENSP00000396554
• ENST00000439701
• ENSP00000413025
• ENST00000644005
• ENSP00000496453

Symbol

• IK1
• IKAROS
• LYF1
• ZNFN1A1
• IK1
• LYF1
• LyF-1
• CVID13
• IKAROS
• PPP1R92
• PRO0758
• ZNFN1A1
• Hs.54452

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
biological process	0.97
PubMedID	0.77
hub protein	0.71
kinase perturbation	0.71
small molecule perturbation	0.7

Protein Classes

PANTHER Classes

Protein / Transcription Factor / Zinc Finger Transcription Factor / Dna-binding Protein Ikaros

Protein / ... / Krab Box Transcription Factor / Dna-binding Protein Ikaros

DTO Classes

Protein / Transcription Factor / Zinc Finger Transcription Factor / C2h2 Zinc Finger Transcription Factor / Krab Box Transcription Factor / Dna-binding Protein Ikaros

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 773.85   (req: < 5)

Gene RIFs: 289   (req: <= 3)

Antibodies: 511   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 773.85   (req: >= 5)

Gene RIFs: 289   (req: > 3)

Antibodies: 511   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 14

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0